- Home
- ETON vs SLDB Comparison
ETON vs SLDB Comparison
Compare ETON & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- SLDB
- Stock Information
- Founded
- ETON 2017
- SLDB 2013
- Country
- ETON United States
- SLDB United States
- Employees
- ETON 31
- SLDB N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ETON Health Care
- SLDB Health Care
- Exchange
- ETON Nasdaq
- SLDB Nasdaq
- Market Cap
- ETON 498.8M
- SLDB 464.1M
- IPO Year
- ETON 2018
- SLDB 2018
- Fundamental
- Price
- ETON $18.25
- SLDB $5.31
- Analyst Decision
- ETON Strong Buy
- SLDB Strong Buy
- Analyst Count
- ETON 3
- SLDB 10
- Target Price
- ETON $29.67
- SLDB $15.00
- AVG Volume (30 Days)
- ETON 261.2K
- SLDB 1.0M
- Earning Date
- ETON 11-06-2025
- SLDB 11-07-2025
- Dividend Yield
- ETON N/A
- SLDB N/A
- EPS Growth
- ETON N/A
- SLDB N/A
- EPS
- ETON N/A
- SLDB N/A
- Revenue
- ETON $58,181,000.00
- SLDB N/A
- Revenue This Year
- ETON $105.25
- SLDB N/A
- Revenue Next Year
- ETON $40.84
- SLDB N/A
- P/E Ratio
- ETON N/A
- SLDB N/A
- Revenue Growth
- ETON 85.40
- SLDB N/A
- 52 Week Low
- ETON $8.24
- SLDB $2.41
- 52 Week High
- ETON $23.00
- SLDB $7.37
- Technical
- Relative Strength Index (RSI)
- ETON 46.28
- SLDB 43.78
- Support Level
- ETON $18.00
- SLDB $5.46
- Resistance Level
- ETON $18.92
- SLDB $6.09
- Average True Range (ATR)
- ETON 0.87
- SLDB 0.35
- MACD
- ETON -0.12
- SLDB -0.06
- Stochastic Oscillator
- ETON 40.66
- SLDB 3.26
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.